Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25


A competing risk model of first failure site after definitive (chemo) radiation therapy for locally advanced non-small cell lung cancer.

Nygård L, Vogelius IR, Fischer BM, Kjær A, Langer SW, Aznar M, Persson GF, Bentzen SM.

J Thorac Oncol. 2018 Jan 18. pii: S1556-0864(18)30006-6. doi: 10.1016/j.jtho.2017.12.011. [Epub ahead of print]


The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis.

Vensby PH, Schmidt G, Kjær A, Fischer BM.

Am J Nucl Med Mol Imaging. 2017 Dec 20;7(6):255-262. eCollection 2017.


Reproducibility of MR-based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer.

Olin A, Ladefoged CN, Langer NH, Keller SH, Löfgren JO, Hansen AE, Kjær A, Langer SW, Fischer BM, Andersen FL.

J Nucl Med. 2017 Nov 9. pii: jnumed.117.198853. doi: 10.2967/jnumed.117.198853. [Epub ahead of print]


Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma.

Rasmussen GB, Håkansson KE, Vogelius IR, Rasmussen JH, Friborg JT, Fischer BM, Schumaker L, Cullen K, Therkildsen MH, Bentzen SM, Specht L.

Acta Oncol. 2017 Nov;56(11):1562-1570. doi: 10.1080/0284186X.2017.1364870. Epub 2017 Aug 25.


A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases.

Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Oturai P, Jensen KE, Mørk ML, Reichkendler M, Højgaard L, Fischer BM.

J Nucl Med. 2017 Nov;58(11):1778-1785. doi: 10.2967/jnumed.116.189183. Epub 2017 Aug 10.


Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.

Guldbrandsen KF, Hendel HW, Langer SW, Fischer BM.

Diagnostics (Basel). 2017 Apr 21;7(2). pii: E23. doi: 10.3390/diagnostics7020023. Review.


Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma.

Rasmussen JH, Nørgaard M, Hansen AE, Vogelius IR, Aznar MC, Johannesen HH, Costa J, Engberg AM, Kjær A, Specht L, Fischer BM.

J Nucl Med. 2017 Jan;58(1):69-74. doi: 10.2967/jnumed.116.180091. Epub 2016 Sep 8.


Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer.

Rasmussen JH, Håkansson K, Vogelius IR, Aznar MC, Fischer BM, Friborg J, Loft A, Kristensen CA, Bentzen SM, Specht L.

Radiother Oncol. 2016 Jul;120(1):76-80. doi: 10.1016/j.radonc.2016.03.005. Epub 2016 Mar 15.


Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer.

Nygård L, Vogelius IR, Fischer BM, Klausen TL, Langer SW, Lonsdale MN, Persson GF, Bentzen SM.

Radiother Oncol. 2016 Mar;118(3):460-4. doi: 10.1016/j.radonc.2016.01.009. Epub 2016 Jan 21.


Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR.

Ladefoged CN, Hansen AE, Keller SH, Fischer BM, Rasmussen JH, Law I, Kjær A, Højgaard L, Lauze F, Beyer T, Andersen FL.

EJNMMI Phys. 2015 Dec;2(1):8. doi: 10.1186/s40658-015-0112-5. Epub 2015 Mar 11.


Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting.

Rasmussen JH, Vogelius IR, Aznar MC, Fischer BM, Christensen CB, Friborg J, Loft A, Kristensen CA, Bentzen SM, Specht L.

Acta Oncol. 2015;54(9):1416-22. doi: 10.3109/0284186X.2015.1061694. Epub 2015 Sep 7.


Geometric distortions of diffusion weighted imaging of the head/neck in combined PET/MR: optimization of image acquisition and post-processing correction for oncology applications.

Hansen AE, Rasmussen J, Johannesen HH, Engberg AM, Andersen FL, Specht L, Kjaer A, Højgaard L, Beyer T, Fischer BM.

EJNMMI Phys. 2014 Jul;1(Suppl 1):A76. doi: 10.1186/2197-7364-1-S1-A76. No abstract available.


Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma.

Rasmussen JH, Vogelius IR, Fischer BM, Friborg J, Aznar MC, Persson GF, Håkansson K, Kristensen CA, Bentzen SM, Specht L.

Head Neck. 2015 Sep;37(9):1274-81. doi: 10.1002/hed.23745. Epub 2014 Jul 21.


Positive correlation of trophic level and proportion of sexual taxa of oribatid mites (Acari: Oribatida) in alpine soil systems.

Fischer BM, Meyer E, Maraun M.

Exp Appl Acarol. 2014 Aug;63(4):465-79. doi: 10.1007/s10493-014-9801-3. Epub 2014 Apr 1.


PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging.

Balyasnikova S, Löfgren J, de Nijs R, Zamogilnaya Y, Højgaard L, Fischer BM.

Am J Nucl Med Mol Imaging. 2012;2(4):458-74. Epub 2012 Oct 15.


Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer.

Bjerregaard JK, Fischer BM, Vilstrup MH, Petersen H, Mortensen MB, Hansen CR, Asmussen JT, Pfeiffer P, Høilund-Carlsen PF.

Acta Oncol. 2011 Nov;50(8):1250-2. doi: 10.3109/0284186X.2011.577095. Epub 2011 May 5. No abstract available.


PET-CT in preoperative staging of lung cancer.

Fischer BM, Lassen U, Højgaard L.

N Engl J Med. 2011 Mar 10;364(10):980-1. doi: 10.1056/NEJMc1012974. No abstract available.


Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial.

Fischer BM, Mortensen J, Hansen H, Vilmann P, Larsen SS, Loft A, Bertelsen AK, Ravn J, Clementsen P, Høegholm A, Larsen KR, Dirksen A, Skov BG, Krasnik M, Højgaard L, Lassen U.

Thorax. 2011 Apr;66(4):294-300. doi: 10.1136/thx.2010.154476. Epub 2010 Dec 17.


Community structure, trophic position and reproductive mode of soil and bark-living oribatid mites in an alpine grassland ecosystem.

Fischer BM, Schatz H, Maraun M.

Exp Appl Acarol. 2010 Nov;52(3):221-37. doi: 10.1007/s10493-010-9366-8. Epub 2010 May 21.

Supplemental Content

Loading ...
Support Center